S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Relay Therapeutics Stock Forecast, Price & News

-2.51 (-6.85 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.20 million shs
Average Volume714,642 shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RLAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Relay Therapeutics logo

About Relay Therapeutics

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$82.65 million
Book Value
$8.48 per share


Net Income
$-52.41 million




Market Cap
$3.16 billion
Next Earnings Date
11/11/2021 (Estimated)
Not Optionable


Overall MarketRank

2.33 out of 5 stars

Medical Sector

242nd out of 1,361 stocks

Biological Products, Except Diagnostic Industry

33rd out of 196 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Relay Therapeutics (NASDAQ:RLAY) Frequently Asked Questions

Is Relay Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Relay Therapeutics stock.
View analyst ratings for Relay Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Relay Therapeutics?

Wall Street analysts have given Relay Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Relay Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Relay Therapeutics' next earnings date?

Relay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Relay Therapeutics

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings results on Thursday, August, 12th. The company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($0.48) by $1.62. The firm earned $0.84 million during the quarter.
View Relay Therapeutics' earnings history

What price target have analysts set for RLAY?

4 Wall Street analysts have issued 1 year target prices for Relay Therapeutics' shares. Their forecasts range from $50.00 to $54.00. On average, they expect Relay Therapeutics' stock price to reach $51.25 in the next year. This suggests a possible upside of 50.2% from the stock's current price.
View analysts' price targets for Relay Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Relay Therapeutics' key executives?

Relay Therapeutics' management team includes the following people:
  • Mr. Alexis A. Borisy, Co-Founder & Independent Chairman (Age 49, Pay $55.62k)
  • Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A., CEO, Pres & Director (Age 47, Pay $987.19k)
  • Dr. Mark Murcko, Co-Founder & Director (Age 61, Pay $181k)
  • Mr. Brian R. Adams J.D., Gen. Counsel & Sec. (Age 47, Pay $568.05k)
  • Dr. Donald A. Bergstrom, Exec. VP and Head of R&D (Age 49, Pay $669.82k)
  • Mr. Thomas Catinazzo, Sr. VP of Fin. (Age 44)
  • Mr. Peter Rahmer, Sr. VP of Corp. Affairs & Investor Relations
  • Dr. Deborah Palestrant Ph.D., VP of Corp. Devel. & Strategy
  • Mr. Andy Porter, Exec. VP & Chief People Officer
  • Mr. Jim Watters Ph.D., Sr. VP of Biology

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), Quidel (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

How do I buy shares of Relay Therapeutics?

Shares of RLAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $34.11.

How much money does Relay Therapeutics make?

Relay Therapeutics has a market capitalization of $3.16 billion and generates $82.65 million in revenue each year.

How many employees does Relay Therapeutics have?

Relay Therapeutics employs 2,020 workers across the globe.

What is Relay Therapeutics' official website?

The official website for Relay Therapeutics is www.relaytx.com.

Where are Relay Therapeutics' headquarters?

Relay Therapeutics is headquartered at 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-370-8837 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.